Jammu Tawi:Indian Immunologicals Ltd (IIL) a wholly owned subsidiary of National Dairy Development Board (NDDB) and a leading biopharmaceutical company in India marks a historic moment in public health with the launch of India’s first indigenously developed Hepatitis A vaccine “Havisure®”. The vaccine represents a significant step forward in India's fight against Hepatitis A and
Corona: Neuartiger Impfstoff von Sanofi und GlaxoSmithKline liefert vielversprechende Ergebnisse spiegel.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from spiegel.de Daily Mail and Mail on Sunday newspapers.
The Atlantic
What ‘Taking the Pandemic Seriously’ Means Now
We need new laws, new policies, and new scientific processes to ensure that we never have to go through this again.
6:00 AM ET
The Atlantic, all agree: We should “take the pandemic seriously.”
I take the pandemic seriously, myself. But at this stage of the crisis, I would like to nail down the terminology. What does it mean for an advanced nation to take a pandemic “seriously”? And are we sure that’s what we’re actually doing?
In the past 13 months, the concept of seriousness has been equated with the level of sacrifice people are willing to stomach. How much of our social and emotional lives are we willing to cancel? How many consecutive days are we willing to stay inside? How many masks are we willing to don? How many schools are our local leaders willing to close? And how many retailers? And how many restaurants? And how many parks, and how many beaches?
The drug maker announced on Thursday (24 December 2020) that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials.
The company is now planning to initiate Phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals.
The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomized, double-blind placebo controlled study.
The vaccine was found to be safe and immunogenic. The trial has been reviewed by an independent Data Safety Monitoring Board (DSMB) and reports have been submitted to Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.